Market Overview:
The global alpha1-proteinase inhibitor market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of respiratory diseases, rising geriatric population, and growing demand for alpha1-proteinase inhibitors in emerging markets. Based on type, the global alpha1-proteinase inhibitor market is segmented into powder and liquid. The powder segment is expected to account for a larger share of the market than the liquid segment during the forecast period. This can be attributed to factors such as ease of use and longer shelf life of powders as compared with liquids. Based on application, the global alpha1-proteinase inhibitor market is segmented into hospital and clinic.
Product Definition:
Alpha1-Proteinase Inhibitor is a protein that helps to prevent the breakdown of other proteins in the body. It is important for preventing tissue damage and maintaining healthy tissue.
Powder:
Powder is a dry solid form of Alpha1-proteinase inhibitor. It has high thermal stability and can withstand pasteurization temperatures. Powder is usually made from vegetable origin such as soy, corn, wheat or potato starch and it contains the same amount of protein as that in liquid form but at a very low concentration compared to liquid one.
Liquid:
Liquid is a colloidal suspension of proteins or polysaccharides. It consists of anionic lipids, such as dicarboxylic acid, phospholipids and monosaccharides. The most commonly used liquid is water-based physiological saline solution (0.9% sodium chloride).
The biological activity of the liquid depends on the type and concentration of protein present in it.
Application Insights:
The market is segmented based on application into hospital, clinic and others. The hospital segment dominated the industry in 2017 due to high usage rates of alpha1-proteinase inhibitors for various conditions, such as acute kidney failure (AKF) and urinary tract infections (UTIs). Alpha1-proteinase inhibitor use is increasing at a significant rate in hospitals across the globe owing to its effectiveness against several diseases. According to WHO, around 30 million people are affected by chronic kidney disease every year globally. In addition, according to data published by CDC in September 2016, around 1 out of 10 women develop some form of UTI during their lifetime while about 25% of women get one or more UTIs each year. Thus, rising prevalence rates drive demand for alpha1-proteinase inhibitor products in clinics as well as hospitals worldwide.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario and high healthcare expenditure are some of the factors responsible for its growth. Moreover, increasing prevalence of cancer is also expected to drive this regional market over the forecast period. For instance, as per American Cancer Society Inc., in 2018 around 2 million new cases were estimated to be diagnosed in U.S., with prostate cancer being one of them (1).
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure coupled with a growing population base that requires advanced treatment options for various diseases including cancer at affordable costs (2). In addition, rapidly developing economies such as China & India are anticipated to fuel demand for several pharmaceutical products including proteinase inhibitors over the next eight years due their large patient pool & evolving medical needs (3).
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is expected to drive the demand for Alpha1-Proteinase Inhibitor in the coming years.
- Growing awareness about benefits of Alpha1-Proteinase Inhibitor: There is a growing awareness among people about the benefits of using Alpha1-Proteinase Inhibitor products. This is likely to boost the market growth in the near future.
- Technological advancements: The market for Alpha1-Proteinase Inhibitor is witnessing rapid technological advancements, which is likely to propel its growth in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Alpha1-Proteinase Inhibitor Market Research Report
By Type
Powder, Liquid
By Application
Hospital, Clinic
By Companies
Baxter, Kamada, Talecris Biotherapeutics, Aventis, CSL Behring, Grifols, Baxter
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
214
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Alpha1-Proteinase Inhibitor Market Report Segments:
The global Alpha1-Proteinase Inhibitor market is segmented on the basis of:
Types
Powder, Liquid
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- Kamada
- Talecris Biotherapeutics
- Aventis
- CSL Behring
- Grifols
- Baxter
Highlights of The Alpha1-Proteinase Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Powder
- Liquid
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alpha1-Proteinase Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alpha1-proteinase inhibitor is a type of medication that helps to prevent the breakdown of proteins in the body. This can help to keep muscles and other tissues healthy.
Some of the major companies in the alpha1-proteinase inhibitor market are Baxter, Kamada, Talecris Biotherapeutics, Aventis, CSL Behring, Grifols, Baxter.
The alpha1-proteinase inhibitor market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alpha1-Proteinase Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alpha1-Proteinase Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alpha1-Proteinase Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alpha1-Proteinase Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alpha1-Proteinase Inhibitor Market Size & Forecast, 2018-2028
4.5.1 Alpha1-Proteinase Inhibitor Market Size and Y-o-Y Growth
4.5.2 Alpha1-Proteinase Inhibitor Market Absolute $ Opportunity
Chapter 5 Global Alpha1-Proteinase Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Alpha1-Proteinase Inhibitor Market Size Forecast by Type
5.2.1 Powder
5.2.2 Liquid
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Alpha1-Proteinase Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Alpha1-Proteinase Inhibitor Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alpha1-Proteinase Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alpha1-Proteinase Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Alpha1-Proteinase Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America Alpha1-Proteinase Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Alpha1-Proteinase Inhibitor Market Size Forecast by Type
9.6.1 Powder
9.6.2 Liquid
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Alpha1-Proteinase Inhibitor Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Alpha1-Proteinase Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe Alpha1-Proteinase Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Alpha1-Proteinase Inhibitor Market Size Forecast by Type
10.6.1 Powder
10.6.2 Liquid
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Alpha1-Proteinase Inhibitor Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Alpha1-Proteinase Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Alpha1-Proteinase Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Alpha1-Proteinase Inhibitor Market Size Forecast by Type
11.6.1 Powder
11.6.2 Liquid
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Alpha1-Proteinase Inhibitor Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Alpha1-Proteinase Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America Alpha1-Proteinase Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Alpha1-Proteinase Inhibitor Market Size Forecast by Type
12.6.1 Powder
12.6.2 Liquid
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Alpha1-Proteinase Inhibitor Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Alpha1-Proteinase Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Alpha1-Proteinase Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Alpha1-Proteinase Inhibitor Market Size Forecast by Type
13.6.1 Powder
13.6.2 Liquid
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Alpha1-Proteinase Inhibitor Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alpha1-Proteinase Inhibitor Market: Competitive Dashboard
14.2 Global Alpha1-Proteinase Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxter
14.3.2 Kamada
14.3.3 Talecris Biotherapeutics
14.3.4 Aventis
14.3.5 CSL Behring
14.3.6 Grifols
14.3.7 Baxter
